Severity of overactive bladder symptoms and response to dose escalation in a randomized, double-blind trial of solifenacin (SUNRISE)
Article first published online: 7 JAN 2013
© 2013 BJU International
Volume 111, Issue 5, pages 804–810, May 2013
How to Cite
Cardozo, L., Amarenco, G., Pushkar, D., Mikulas, J., Drogendijk, T., Wright, M., Compion, G. and SUNRISE Study Group (2013), Severity of overactive bladder symptoms and response to dose escalation in a randomized, double-blind trial of solifenacin (SUNRISE). BJU International, 111: 804–810. doi: 10.1111/j.1464-410X.2012.11654.x
- Issue published online: 12 APR 2013
- Article first published online: 7 JAN 2013
- Astellas Pharma Europe Ltd
- 15Total urgency score (TUS) as a measure of frequency and urgency in SUNRISE. Urology 2010; 76 (Suppl. 3a): 592. Abstract UP-2.35, , et al.
- 16The STAR study: analysis of symptom severity and treatment response in overactive bladder. Int Urogynecol J 2006; 17 (Suppl. 2): Abstr 380, S88, , et al.
- 17Effetcs of solifenacin on overactive bladder symptoms, symptom bother and other patient-reported outcomes: results from VIBRANT – a double-blind, placebo-controlled trial. Int J Clin Pract 2009; 63: 1702–1714, , et al.